|Bid||0.00 x 1000|
|Ask||0.00 x 1100|
|Day's Range||114.21 - 117.98|
|52 Week Range||104.28 - 134.55|
|Beta (3Y Monthly)||1.45|
|PE Ratio (TTM)||14.16|
|Earnings Date||Jan 28, 2019 - Feb 1, 2019|
|Forward Dividend & Yield||0.96 (0.82%)|
|1y Target Est||134.88|
NEW YORK, Nov. 01, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The Zacks Analyst Blog Highlights: Comcast, ConocoPhillips, Delta Air Lines, ServiceNow and Zimmer Biomet
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
Zimmer (ZBH) delivered earnings and revenue surprises of 1.87% and 0.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Warsaw, Indiana-based company said it had net income of 79 cents. Earnings, adjusted for one-time gains and costs, were $1.63 per share. The results exceeded Wall Street expectations. ...
- Net sales of $1.837 billion for the third quarter represent an increase of 1.3% over the prior year period, and an increase of 2.3% on a constant currency basis - Diluted EPS for the third quarter were ...
Short interest is extremely low for ZBH with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZBH. The $3.07 billion in inflows that ETFs holding ZBH received over the last one-month is a decline from earlier in the period and among the weakest of the past year.
The Shuman Law Firm announces that it is investigating potential shareholder claims against certain officers and directors of Zimmer Biomet Holdings, Inc. (“ZBH” or the “Company”) (Nasdaq: ZBH). ZBH designs, manufactures, and markets musculoskeletal healthcare products. The lawsuit alleges that these defendants made materially false statements relating to the financial performance of ZBH during the summer and fall of 2016 by concealing compliance issues at a key factory.
Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.
Zimmer (ZBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Barclays initiates coverage on medical technology names with a positive view. Top picks include Abbott Labs, Boston Scientific, Stryker, and Medtronic.
As part of its latest healthcare-focused venture, Apple has teamed up with Zimmer Biomet on an app designed for knee and hip replacement patients. The app, called mymobility, works with the Apple Watch and iPhone, and it provides patients with guidance before and after their surgeries, tracks their activity, allows surgeons to monitor that activity and lets patients connect with their surgeons through secure messaging. "We believe one of the best ways to empower consumers is by giving them the ability to use their health and activity information to improve their own care," Apple COO Jeff Williams said in a statement.
Four hospitals and more than a dozen other medical facilities in states including Massachusetts, California, Colorado and Michigan will receive stats including heart rate, steps taken and standing hours from patients waiting for or recovering from hip and knee replacement surgery. The multi-year study in collaboration with Apple Inc will allow doctors and their teams to gauge better how well patients are following prescribed physiotherapy or regimes ahead of surgery or recovering afterwards. More than a million knee and hip replacements occur every year in the United States, making them two of the most common surgeries Americans undergo.
Up to 10,000 Americans due to have hip or knee replacements will be able to funnel basic health data directly from their Apple Watches to their surgeons under a new app being tested by orthopedics company Zimmer Biomet. Four hospitals and more than a dozen other medical facilities in states including Massachusetts, California, Colorado and Michigan will receive stats including heart rate, steps taken and standing hours from patients waiting for or recovering from hip and knee replacement surgery. The multi-year study in collaboration with Apple Inc will allow doctors and their teams to gauge better how well patients are following prescribed physiotherapy or regimes ahead of surgery or recovering afterwards.
Apple has made health -- and helping people keep tabs on theirs -- a cornerstone of how it is presenting the benefits of its newest Apple Watch, and today comes news of another way that this is taking shape. Zimmer Biomet, a world leader in developing the components and systems for joint replacements, says that it is working with Apple on a new clinical study focused on people who get knee and hip replacements. The trial will come in three stages, and within two years, Zimmer Biomet projects that there to be up to 10,000 people involved, Ted Spooner, Zimmer Biomet's vice president of connected health, said in an interview.
Apple is teaming up with medical device company Zimmer Biomet for a new clinical study and Apple Watch app. The goal is to better understand how patients should prepare for, and recover from, common knee and hip replacement procedures. As Apple AAPL pushes deeper into health care with the Apple Watch, the company is developing a plan to help people who are recovering from knee and hip replacement surgeries.
Last year, a Securities Class Action Complaint was filed on behalf of those who purchased Zimmer Biomet Holdings, Inc. (ZBH) securities ("Zimmer"), between June 7, 2016, and November 7, 2016. On September 26, 2018, Judge Philip P. Simon denied Zimmers's motion to dismiss.
WARSAW, Ind. , Oct. 1, 2018 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter sales and earnings conference call will be broadcast over the Internet on ...
WARSAW, Ind., Sept. 13, 2018 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2018. The cash dividend of $0.24 per share is payable on October 31, 2018 to stockholders of record as of the close of business on September 28, 2018. Future declarations of dividends are subject to approval of the Board of Directors and may be adjusted as business needs or market conditions change.